载体即药物：石强强/宫宁强等开发pLNP，协同增强mRNA癌症免疫治疗效果

Core Viewpoint - The article discusses a novel approach in mRNA-based cancer immunotherapy, focusing on the use of prodrug ionizable lipid nanoparticles (pLNP) to enhance T cell activation while preventing T cell exhaustion, thereby improving anti-tumor responses [2][3][6]. Group 1: Research Overview - A research team from the University of Pennsylvania developed pLNP that combines an IDO inhibitor and IL-12 mRNA, achieving a synergistic effect in cancer treatment [3][8]. - The pLNP serves as both a drug and a delivery vehicle, where the ionizable lipid itself acts as a prodrug, releasing the IDO inhibitor upon cellular entry to inhibit T cell exhaustion [6][8]. Group 2: Mechanism of Action - The pLNP facilitates dual action: it activates T cells by delivering IL-12 mRNA and prevents their exhaustion by releasing the IDO inhibitor, effectively acting as both a "gas pedal" and a "brake release" in the tumor microenvironment [6][8]. - This coordinated action leads to increased T cell infiltration and reduced exhaustion in a mouse model of colon cancer, resulting in complete regression of primary tumors and activation of systemic immune responses [8]. Group 3: Implications for Cancer Immunotherapy - The integration of small molecule drugs and mRNA therapies within a single lipid nanoparticle represents a significant advancement in cancer immunotherapy, providing a powerful and innovative platform for treatment [3][8].